IL247869B - Formulations of factor ix that have been lyophilized - Google Patents

Formulations of factor ix that have been lyophilized

Info

Publication number
IL247869B
IL247869B IL247869A IL24786916A IL247869B IL 247869 B IL247869 B IL 247869B IL 247869 A IL247869 A IL 247869A IL 24786916 A IL24786916 A IL 24786916A IL 247869 B IL247869 B IL 247869B
Authority
IL
Israel
Prior art keywords
formulations
lyophilized factor
lyophilized
factor
Prior art date
Application number
IL247869A
Other languages
English (en)
Hebrew (he)
Other versions
IL247869A0 (en
Original Assignee
Bioverativ Therapeutics Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL247869(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc, Biogen Ma Inc filed Critical Bioverativ Therapeutics Inc
Publication of IL247869A0 publication Critical patent/IL247869A0/en
Publication of IL247869B publication Critical patent/IL247869B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Monitoring And Testing Of Transmission In General (AREA)
  • Mobile Radio Communication Systems (AREA)
IL247869A 2014-03-24 2016-09-18 Formulations of factor ix that have been lyophilized IL247869B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24
PCT/US2015/022141 WO2015148444A1 (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Publications (2)

Publication Number Publication Date
IL247869A0 IL247869A0 (en) 2016-11-30
IL247869B true IL247869B (en) 2020-02-27

Family

ID=54196282

Family Applications (3)

Application Number Title Priority Date Filing Date
IL247869A IL247869B (en) 2014-03-24 2016-09-18 Formulations of factor ix that have been lyophilized
IL272257A IL272257B (en) 2014-03-24 2020-01-26 Formulations of factor ix that have been lyophilized
IL281197A IL281197B (en) 2014-03-24 2021-03-02 Formulations of factor ix that have been lyophilized

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL272257A IL272257B (en) 2014-03-24 2020-01-26 Formulations of factor ix that have been lyophilized
IL281197A IL281197B (en) 2014-03-24 2021-03-02 Formulations of factor ix that have been lyophilized

Country Status (16)

Country Link
US (3) US10772942B2 (OSRAM)
EP (1) EP3123090A4 (OSRAM)
JP (4) JP7058940B2 (OSRAM)
KR (1) KR102385372B1 (OSRAM)
AR (1) AR099838A1 (OSRAM)
AU (3) AU2015236340B2 (OSRAM)
CA (1) CA2943034C (OSRAM)
CL (1) CL2016002386A1 (OSRAM)
EA (2) EA202092926A3 (OSRAM)
IL (3) IL247869B (OSRAM)
MA (1) MA39779A (OSRAM)
MX (2) MX387269B (OSRAM)
PH (1) PH12016501877A1 (OSRAM)
SG (3) SG10201808249VA (OSRAM)
TW (1) TWI700101B (OSRAM)
WO (1) WO2015148444A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707600XA (en) * 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
US10772942B2 (en) * 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
CN110520150A (zh) * 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
MX421254B (es) * 2017-07-11 2025-02-10 Universal Stabilization Tech Inc Método para la conservación de material biológico.
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
JP2023514540A (ja) 2020-02-04 2023-04-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 凍結乾燥医薬品の目標残留水分含有量
MX2022014163A (es) * 2020-05-11 2023-02-22 Alkermes Pharma Ireland Ltd Composiciones de polipeptido de fusion il-2 y metodos para fabricarlas y usarlas.
CN118557531B (zh) * 2024-08-02 2024-10-18 成都蓉生药业有限责任公司 一种重组人凝血因子VIII-Fc融合蛋白冻干制剂的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0627924B1 (en) * 1992-10-02 2000-12-27 Genetics Institute, Inc. Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (OSRAM) 1996-10-16 2000-09-09 Alza Corp
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
EP1219298A4 (en) 1999-09-17 2003-06-11 Takeda Chemical Industries Ltd METHOD FOR PRODUCING PROTEIN POWDER
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
HUP0401534A3 (en) 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
WO2005058283A2 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
PT1827483E (pt) 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
JP4860703B2 (ja) * 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
PL3225233T3 (pl) * 2005-11-01 2019-12-31 Wyeth Llc Roztwór chlorku sodu do odtwarzania leku
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
HUE030567T2 (en) 2006-03-24 2017-05-29 Biogen Hemophilia Inc PC5 is a factor IX propeptide processing enzyme
NZ568728A (en) 2006-04-04 2011-09-30 Shire Pharmaceuticals Ireland Ltd A process for concentration of a aryl sulfatase A
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US8015841B2 (en) 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
RU2481823C2 (ru) 2007-12-21 2013-05-20 Инспирейшн Биофармасьютикалс, Инк. Стабилизированные составы, содержащие фактор ix и трегалозу
CA2709960A1 (en) 2007-12-27 2009-07-09 Baxter International Inc. Chemically modified factor ix
CN102083856A (zh) 2008-04-16 2011-06-01 拜耳医药保健有限公司 经修饰的因子ix多肽及其用途
KR20110015551A (ko) 2008-04-16 2011-02-16 바이엘 헬스케어 엘엘씨 제ｉｘ인자의 부위-지정 변형
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
NZ588854A (en) 2008-04-24 2011-12-22 Celtic Pharma Peg Ltd Factor ix-polyethylene conjugates with extended half-lives
EP3572073B1 (en) 2008-08-05 2023-12-20 Wyeth LLC Lyophilization above collapse
GB2479069B (en) 2008-09-24 2012-07-25 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
WO2010148337A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
CN103140237A (zh) * 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
WO2012109429A2 (en) 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
US20150252345A1 (en) * 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations

Also Published As

Publication number Publication date
BR112016021777A2 (pt) 2017-10-03
AU2022215218B2 (en) 2025-12-18
AU2020202863A1 (en) 2020-05-21
AU2020202863B2 (en) 2022-09-01
AU2015236340A1 (en) 2016-09-29
MX2021012939A (es) 2021-11-25
EA038573B1 (ru) 2021-09-16
US20170173122A1 (en) 2017-06-22
JP7503583B2 (ja) 2024-06-20
EA201691807A1 (ru) 2017-03-31
CL2016002386A1 (es) 2017-06-23
AU2022215218A1 (en) 2022-09-01
US10772942B2 (en) 2020-09-15
SG11201607642RA (en) 2016-10-28
KR102385372B1 (ko) 2022-04-11
EP3123090A4 (en) 2017-12-13
CA2943034A1 (en) 2015-10-01
IL247869A0 (en) 2016-11-30
SG10201808249VA (en) 2018-10-30
AR099838A1 (es) 2016-08-24
EP3123090A1 (en) 2017-02-01
EA202092926A2 (ru) 2021-07-30
MX2016012447A (es) 2017-01-06
IL281197B (en) 2022-06-01
JP7759978B2 (ja) 2025-10-24
CA2943034C (en) 2022-06-14
IL272257A (en) 2020-02-27
MX387269B (es) 2025-03-18
JP2017510585A (ja) 2017-04-13
JP2022044689A (ja) 2022-03-17
EA202092926A3 (ru) 2021-10-29
TWI700101B (zh) 2020-08-01
PH12016501877A1 (en) 2016-12-19
US20210069307A1 (en) 2021-03-11
IL281197A (en) 2021-04-29
US12128092B2 (en) 2024-10-29
JP2020063313A (ja) 2020-04-23
US20250121042A1 (en) 2025-04-17
TW201605492A (zh) 2016-02-16
IL272257B (en) 2021-03-25
AU2015236340B2 (en) 2020-02-06
MA39779A (fr) 2017-02-01
KR20160137577A (ko) 2016-11-30
JP7058940B2 (ja) 2022-04-25
JP2024053015A (ja) 2024-04-12
NZ724351A (en) 2023-10-27
WO2015148444A1 (en) 2015-10-01
SG10201913735SA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
TWD174427S (zh) 刮勺
GB201407934D0 (en) Formulation
GB2538413B (en) Blower
IL281197B (en) Formulations of factor ix that have been lyophilized
GB2530868B (en) Blower
GB201419091D0 (en) Formulations
IL276960B (en) Lyophilized formulations for factor xa antidote
GB201419261D0 (en) Formulations
ZA201702401B (en) Composition with reduced immunogenicity
GB201407384D0 (en) Formulation
IL248835A0 (en) A preparation of ciritinib
GB201402448D0 (en) Novel formulation
GB201511301D0 (en) Formulation
IL251362A0 (en) formulation
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
GB201410184D0 (en) Odontalgic preparation
TWM490682U (en) Storagable extension-cord socket structure
GB201405857D0 (en) Immunogenic formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed